**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1 - 5. (Cancelled).

Claim 6. (Currently amended) A compound according to formula V in free or pharmaceutically acceptable salt form



wherein

$R_{11}$ is pyrimidyl;

X is $-NR_6-Y-$, -O- or -S-,

wherein $R_6$ is H, $C_1$-$C_4$alkyl, $C_6$-$C_{18}$aryl, $C_3$-$C_{18}$heteroaryl, $C_7$-$C_{19}$aralkyl or $C_4$-$C_{19}$heteroaralkyl, and -Y- is $C_1$-$C_4$alkylene or a direct bond;

$R_{12}$ is phenyl, optionally substituted by one or more substituents, each of which is independently selected from

halo,

$CF_3$,

cyano,

amido or thioamido which is optionally mono- or di-N-substituted by $C_1$-$C_4$alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally $C_1$-$C_4$alkyl $C_1$-$C_4$alkylcarbonyl or $C_1$-$C_4$alkylthiocarbonyl substituted,

carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted $C_1$-$C_{10}$alkoxy, $C_2$-$C_{10}$alkenoxy, $C_2$-$C_{10}$alkynoxy, $C_3$-$C_7$cyclalkoxy, $C_5$-$C_7$cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester, optionally mono- or di-$C_1$-$C_4$alkyl-substituted-$C_0$-$C_1$alkyl optionally $C_1$-$C_4$alkyl- or $C_3$-$C_5$cycloalkyl-substituted-carbonyl or -thiocarbonyl,

optionally halo-substituted-$C_1$-$C_4$alkoxy, $C_2$-$C_4$alkenoxy, $C_2$-$C_4$alkynoxy, $C^3_3$-$C^5_5$cycloalkoxy or $C^3_3$-$C^5_5$cyclothioalkoxy,

optionally halo substituted $C_1$-$C_4$ alkyl,

oxycarbonyl or optionally N-$C_1$-$C_4$alkyl-substituted aminocarbonyl both of which are optionally $C_1$-$C_4$alkyl or $C_3$-$C_5$cycloalkyl substituted (including thiocarbonyl analogues thereof),

optionally mono- or di-$C_1$-$C_4$alkyl-substituted -$C_0$-$C_1$alkylamine which is optionally mono- or di-N-$C_1$-$C_4$ alkyl substituted,

optionally mono- or di-$C_1$-$C_4$alkyl-substituted-$C_0$-$C_1$alkyl optionally N-$C_1$-$C_4$alkyl-substituted amino-carbonyl or -thiocarbonyl,

optionally N-$C_1$-$C_4$ alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by

optionally mono- or -di-N-$C_1$-$C_4$alkyl-substituted amino,

a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally $C_1$-$C_4$ alkyl $C_1$-$C_4$alkylcarbonyl or $C_1$-$C_4$alkylthiocarbonyl substituted, or

sulphinyl or sulphonyl optionally substituted by

optionally halo-substituted-$C_1$-$C_4$alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl,

optionally mono- or di-N-$C_1$-$C_4$alkyl-substituted amino,

a nitrogen atom which form a heterocyclic rind of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally $C_1$-$C_4$alkyl $C_1$-$C_4$alkylcarbonyl or $C_1$-$C_4$alkylthiocarbonyl substituted;

$R_{13}$ is H, amino, $C_1$-$C_{10}$alkyl, $C_3$-$C_{10}$cycloalkyl, $C_3$-$C_{18}$heterocycloalkyl, $C_6$-$C_{18}$aryl, or $C_3$-$C_{18}$heteroaryl all optionally substituted by up to 4 substituents separately selected from $C_1$-$C_4$alkyl, halogen, halo-substututed-$C_1$-$C_4$alkyl, hydroxyl, $C_1$-$C_4$alkoxy, $C_1$-$C_4$alkylthio, $C_6$-$C_{18}$aryl, $C_3$-$C_{18}$heteroaryl, $C_6$-$C_{18}$aryl$C_1$-$C_4$alkyl, $C_3$-$C_{18}$heteroaryl$C_1$-$C_4$alkyl, $C_3$-$C_{18}$heterocycloalkyl or optionally mono- or di-N-$C_1$-$C_4$alkyl substituted amino all of which are optionally substituted by halo, hydroxyl, $C_1$-$C_4$alkyl, $C_1$-$C_4$alkoxy or $C_1$-$C_4$alkoxycarbonyl; and

$R_{14}$ is $C_1$-$C_{10}$alkyl, $C_6$-$C_{18}$aryl, $C_3$-$C_{18}$heteroaryl, or $C_3$-$C_{12}$cycloalkyl optionally substituted by up to 3 substituents separately selected from $C_1$-$C_4$alkyl, halogen, halo-substitued-$C_1$-$C_4$alkyl, hydroxyl, $C_1$-$C_4$alkoxy, $C_1$-$C_4$alkylthio, optionally mono- or di-N-$C_1$-$C_4$alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N[[,]]

~~and pharmaceutically-acceptable and -cleavable esters thereof and acid addition sales thereof~~.

Claim 7. (Currently amended) A compound according to claim 6 of formula V' in free or pharmaceutically acceptable salt form



V'

wherein

$R_{14}$' is phenyl or $C_3$-$C_7$cycloalkyl each of which is optionally mono-substituted by halogen, $C_1$-$C_4$alkyl, $C_1$-$C_4$alkoxy, hydroxyl, trihalomethyl optionally mono- or di-N-$C_1$-$C_4$alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N;

$R_{10}$ is halogen, $CF_3$, $C_1$-$C_4$alkyl or $C_1$-$C_4$alkoxy;

$R_{13}$' is pyridyl, pyrimidyl, piperazinyl, piperidinyl, $NR_9R_{10}$, $-CH_2OH$, $CH_2NR_{15}R_{16}$, $-CH2CH_2R_{15}R_{16}$, or Het-$C_1$-$C_4$alkyl-,

wherein

$R_9$ and $R_{10}$ are separately selected from H, $C_1$-$C_4$alkyl, $C_6$-$C_{18}$aryl, $C_3$-$C_{18}$ heteroaryl, $C_6$-$C_{18}$aryl$C_1$-$C_4$alkyl, $C_3$-$C_{18}$heteroaryl$C_1$-$C_4$alkyl all of which are optionally substituted by halo, hydroxyl, $C_1$-$C_4$alkyl, $C_1$-$C_4$alkoxy, $C_1$-$C_4$alkoxycarbonyl[[,]] ;

~~$R_{11}$ and $R_{12}$ are separately selected from H or $C_1$-$C_6$alkyl, and~~

Het ~~is N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom (e.g. O,S or N)~~ is a N-heterocyclyl containing from 5 to 7 ring atoms where said ring atoms optionally containing a further heteroatom selected from the group consisting of O, S, and N;

$R_{15}$ and $R_{16}$ are independently selected from H and $C_1$-$C_4$ alkyl;

X" is -NH-Y'-, -O- or -S-, where Y' is '$CH_2$-, $-CH_2-CH_2$-, $-CH_9(CH_3)$- or a direct bond~~, and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof~~.

Claim 8. (Currently amended) A compound according to claim 6 selected from:

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidino-N-2-ethyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(N,N-diethylamino-N-2-ethyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino-N-2-ethyl)imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(isopropylamino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyrrolidino-N-2-ethyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-pyridyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(aminoimidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-NH-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino- 4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-(4-methyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-(S)-phenylethyl)amino-4-pyrimidinyl)-5-(4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-((4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclobutylamino-4-pyrimidinyl)-5-((4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopropylamino-4-pyrimidinyl)-5-((4-(2-hydroxy-2-methyl)propyl-1-piperazinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(4-piperidinyl) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-methyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-(2-hydroxy-2-methyl)propyl-4-piperidinyl)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(benzylamino) imidazo[4,5-b]pyridine;

2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(morpholino) imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(3-fluorophenyl amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(pyridyl-4-amino)imidazo[4,5-b]pyridine;
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(1-ethoxycarbonyl piperidine-4-amino)imidazo[4,5-b]pyridine; and
2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidine-4-amino)imidazo[4,5-b]pyridine[[;]].

Claim 9. (Currently amended) A process for the production of

(i) ~~an Agent of the Invention~~ a compound of formula V" in free or pharmaceutically acceptable salt form




wherein

$R_{11}$ is pyrimidyl;[[,]]

$R_{12}$[[,]] is phenyl, optionally substituted by one or more substituents, each of which is independently selected from

halo,

$CF_3$,

cyano,

amido or thioamido which is optionally mono- or di-N-substituted by $C_1$-$C_4$alkyl or the N atom of which forms a 5-7 membered heterocyclic ring optionally containing an additional hetero atom selected from O, S or N which N is optionally $C_1$-$C_4$alkyl $C_1$-$C_4$alkylcarbonyl or $C_1$-$C_4$alkylthiocarbonyl substituted,

carboxylate or thiocarboxylate optionally in the form of an optionally halo-substituted $C_1$-$C_{10}$alkoxy, $C_2$-$C_{10}$alkenoxy, $C_2$-$C_{10}$alkynoxy, $C_3$-$C_7$cyclalkoxy, $C_5$-$C_7$cycloalkenoxy, aryloxy, arylalkoxy, heteroaryloxy or heteroarylalkoxy ester, optionally mono- or di-$C_1$-$C_4$alkyl-substituted-$C_0$-$C_1$alkyl optionally $C_1$-$C_4$alkyl- or $C_3$-$C_5$cycloalkyl-substituted-carbonyl or -thiocarbonyl,

optionally halo-substituted-$C_1$-$C_4$alkoxy, $C_2$-Calkenoxy, $C_2$-Calkynoxy, $C_3$-$C_5$cycloalkoxy or $C_3$-$C_5$cyclothioalkoxy,

optionally halo substituted $C_1$-$C_4$ alkyl,
oxycarbonyl or optionally N-$C_1$-$C_4$alkyl-substituted aminocarbonyl both of which are optionally $C_1$-$C_4$alkyl or $C_3$-$C_5$cycloalkyl substituted (including thiocarbonyl analogues thereof),
optionally mono- or di-$C_1$-$C_4$alkyl-substituted -$C_0$-$C_1$alkylamine which is optionally mono- or di-N-$C_1$-$C_4$ alkyl substituted,
optionally mono- or di-$C_1$-$C_4$alkyl-substituted-$C_0$-$C_1$alkyl optionally N-$C_1$-$C_4$alkyl-substituted amino-carbonyl or -thiocarbonyl,
optionally N-$C_1$-$C_4$ alkyl-substituted amino-sulphinyl or -sulphonyl optionally substituted by
optionally mono- or -di-N-$C_1$-$C_4$alkyl-substituted amino,
a nitrogen atom which form a heterocyclic ring of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally $C_1$-$C_4$ alkyl $C_1$-$C_4$alkylcarbonyl or $C_1$-$C_4$alkylthiocarbonyl substituted, or
sulphinyl or sulphonyl optionally substituted by
optionally halo-substituted-$C_1$-$C_4$alkyl, $C_2$-$C_4$ alkenyl, $C_2$-$C_4$ alkynyl,
optionally mono- or di-N-$C_1$-$C_4$alkyl-substituted amino,
a nitrogen atom which form a heterocyclic rind of 5 to 7 members optionally containing an additional heteroatom selected from O, S or N which N is optionally $C_1$-$C_4$alkyl $C_1$-$C_4$alkylcarbonyl or $C_1$-$C_4$alkylthiocarbonyl substituted;

$R_{14}$ is $C_1$-$C_{10}$alkyl, $C_6$-$C_{18}$aryl, $C_3$-$C_{18}$heteroaryl, or $C_3$-$C_{12}$cycloalkyl optionally substituted by up to 3 substituents separately selected from $C_1$-$C_4$alkyl, halogen, halo-substitued-$C_1$-$C_4$alkyl, hydroxyl, $C_1$-$C_4$alkoxy, $C_1$-$C_4$alkylthio, optionally mono- or di-N-$C_1$-$C_4$alkyl substituted amino, or by N-heterocyclyl containing from 5 to 7 ring atoms and optionally containing a further hetero atom selected from O, S or N ~~and~~ ;

X is -$NR_6$-Y-, -O- or -S-, wherein $R_6$ is H, $C_1$-$C_4$alkyl, $C_6$-$C_{18}$aryl, $C_3$-$C_{18}$heteroaryl, $C_7$-$C_{19}$aralkyl or $C_4$-$C_{19}$heteroaralkyl, and -Y- is $C_1$-$C_4$alkylene or a direct bond;
~~are as previously defined and~~

$R_{13}$" is -$CH_2$-$CH_2NR_{15}R_{16}$ or - $CH_2$-$CH_2$-Het wherein

$R_{15}$[[,]] and $R_{16}$ are independently selected from H and $C_1$-$C_4$ alkyl; and

Het ~~are as previously defined~~ is a N-heterocyclyl containing from 5 to 7 ring atoms where said ring atoms optionally containing a further heteroatom selected from the group consisting of O, S, and N;

comprising reacting a corresponding vinyl precursor of formula VI



VI

wherein $R_{11}$, $R_{12}$, $R_{14}$ and X are as previously defined with the corresponding amine of formula $HNR_{15}R_{16}$ or N-heterocycloalkyl ring compound;

(ii) ~~an Agent of the Invention~~ a compound of formula V according to claim 6



V

wherein $R_{13}$ is aryl or heteroaryl comprising arylation or heteroarylation of a compound of formula VII



VII

wherein $R_{11}$, $R_{12}$, $R_{14}$ and X are as previously defined in claim 6;

(iii) ~~an Agent of the Invention~~ a compound of formula V according to claim 6

wherein $R_{13}$ is -N-heterocycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycloalkyl, -NH-($C_1$-$C_4$alkyl)-heterocycloalkyl, -NH-($C_1$-$C_4$alkyl)-aryl, -NH-($C_1$-$C_4$alkyl)-heteroaryl, or -NH-($C_1$-$C_4$alkyl)-heterocycloalkyl comprising coupling a corresponding chloroprecursor compound of formula VII, as defined above, with the corresponding N-heterocycloalkyl compound or amine;

(iv) ~~an Agent of the Invention~~ a compound of formula V according to claim 6

in which $R_{13}$ is $-NH_2$, comprising reacting the corresponding methyl sulphinyl compound of formula VIII'



VIII'

wherein $R_{11}$ and $R_{12}$ are as previously defined in claim 6;

(v) ~~an Agent of the Invention~~ a compound of formula V according to claim 6

in which $R_{13}$ is piperazinyl, comprising reacting a corresponding methylsulphinyl compound of formula VIII"



VIII"

wherein $R_{11}$ and $R_{12}$ are as previously defined in claim 6 and P is an N protecting group, with the corresponding amine of formula $R_{14}$-$NH_2$; and

(vi) recovering the resultant compounds of formula (V") or (V) in free or pharmaceutically acceptable salt form.

Claims 10 - 13. (Cancelled).